View Risk


Article data
Cai (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
https://doi.org/10.1016/j.eng.2020.03.007
https://www.sciencedirect.com/science/article/pii/S2095809920300631?via%3Dihub

Results
Treatment
Treatment for COVID-19 (Treated with favipiravir vs. Treated with lopinavir/ritonavir)
Virus clearance
Hazard ratio: 3.434 (1.162-10.148) Adjusted model

Study characteristics

China

Non-randomized clinical trial

Primary data collection

80

laboratory-confirmed COVID-19 patients

56 patients with laboratory-confirmed COVID-19 were screened, of which 35 were eligible for the FPV arm of the study. A total of 91 laboratory-confirmed COVID-19 patients who had started treatment with LPV/RTV between 24 January and 30 January 2020 were screened, of which 45 were eligible for the control arm of this study.

Total

14 Day


Results

Virus clearance

0

A multivariate Cox regression model was used to explore the independent factors affecting viral clearance. The time of viral clearance was set as the TIME variable, viral clearance (0 = no, 1 = yes) was set as the status, and the variables that were significant (P < 0.10) in the univariate Cox analysis or were professionally significant (including age, and whether underlying diseases were present or not) were set as independent variable

Treatment

Treatment for COVID-19

effects of Favipiravir (FPV) versus Lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19

Treated with lopinavir/ritonavir

Treated with favipiravir

Hazard ratio

3.434 (1.162-10.148)

No

Yes

Yes

WBC. Hp, PLT, Neutrophils, T lymphocyte count , CD8+ T lymphocyte , Time from onset to treatment , FPV versus LPV/RTV , Age , Underlying diseases


Other information

none

Average

No

Go Back